| Literature DB >> 28666360 |
Sue A Brown1, Marc D Breton1, Stacey M Anderson1, Laura Kollar1, Patrick Keith-Hynes2, Carol J Levy3, David W Lam3, Camilla Levister3, Nihat Baysal4, Yogish C Kudva5, Ananda Basu5, Vikash Dadlani5, Ling Hinshaw5, Shelly McCrady-Spitzer5, Daniela Bruttomesso6, Roberto Visentin7, Silvia Galasso6, Simone Del Favero7, Yenny Leal7, Federico Boscari6, Angelo Avogaro6, Claudio Cobelli7, Boris P Kovatchev1.
Abstract
Context: Closed-loop control (CLC) for the management of type 1 diabetes (T1D) is a novel method for optimizing glucose control, and strategies for individualized implementation are being developed. Objective: To analyze glycemic control in an overnight CLC system designed to "reset" the patient to near-normal glycemic targets every morning. Design: Randomized, crossover, multicenter clinical trial. Participants: Forty-four subjects with T1D requiring insulin pump therapy. Intervention: Sensor-augmented pump therapy (SAP) at home vs 5 nights of CLC (active from 23:00 to 07:00) in a supervised outpatient setting (research house or hotel), with a substudy of 5 nights of CLC subsequently at home. Main Outcome Measure: The percentage of time spent in the target range (70 to 180 mg/dL measured using a continuous glucose monitor).Entities:
Mesh:
Substances:
Year: 2017 PMID: 28666360 PMCID: PMC5630248 DOI: 10.1210/jc.2017-00556
Source DB: PubMed Journal: J Clin Endocrinol Metab ISSN: 0021-972X Impact factor: 5.958